Speakers

Ian Talmage has held several significant positions in the pharmaceutical industry, in which he has gained Strategic Planning, Partnering and Global Launch experience. He currently works with Bayer where he has held senior positions in both Pharma Strategic Planning and Global Strategic Marketing. Prior to this, Ian worked with a number of global pharma organisations, including Astra where he carried commercial responsibility for their global Cardiovascular and Gastrointestinal interests, Novartis where he held senior positions in both global marketing and business development & licensing, SmithKline where he worked in a number of roles including International strategic marketing and brand management and in Yamanouchi where he carried responsibility for their European Marketing Team.

His launch management experience includes a number of key global brands, including 'Losec'/'Prilosec' and 'Diovan', and he has gathered significant cross-TA experience in areas including Gastroenterology, Cardiology, Oncology, Respiratory, Transplantation, CNS, Dermatology and Ophthalmology. In addition, Ian has worked in many different geographies, having been based in the UK, US, Sweden, Switzerland, The Netherlands and now Germany.

Qualified with a hospital pharmacy background and currently working as the Formulary Advisor for Surrey & Sussex Healthcare NHS Trust, Omar currently leads the regional Joint Drugs & Therapeutics Committee and sits on both the PCT Area Prescribing Committee as well as the PCT Medicines Management Steering Group. Omar is a Senior Lecturer at the University of Portsmouth PGDip/MSc Pharmacy Programme and last year became both Lecturer & Examiner on the Independent Prescribing V300 Course at the University of Surrey. He has also taken up position as course module tutor for the Primary Care Training Centre. Omar has 27 publications to date (prescribing anagement within various long term conditions & health economics) and has authored 2 booklets on implementation of NICE Guidance & TAG documents. He has spoken at various Medical Conferences within the UK, Europe and occasionally further a field and has been appointed to the NHS Advisory Board for Pharmaceutical Field Magazine. He is an Editorial Content Adviser to both Guidelines (national publication for NHS implementation of prescribing pathways) as well as Prescriber (national publication for NHS Medicines Management Teams) and also sits on the CPPE Advisory Board Task Force. Most recently in 2010, Omar was appointed a position on the External Reference Group on
Cost Impact Modelling for NICE and has starting advising the US Embassy on ‘Value Based Pricing’ (hosted by the UK Department of Trade & Industry) which will replace the PPRS Roadmap for Drug Pricing in the UK by 2014.

Andrea is the business manager and nurse lead for the StHealth Practice Based Commissioning Consortium, which covers 24 practices in St Helens, Merseyside, UK with a combined population of 138,000 patients.

StHealth is a Pathfinder Clinical Commissioning organisation whose aims are to improve patient outcomes whilst reducing costs. It was shortlisted as Primary Care Organisation of the Year by the HSJ in 2010 and jointly, with GSK won the ABPI joint working award 2010 and the Pharma Times Joint Working Award 2010

Andrea was a founder board member for StHealth and remained in this position for 4 years, until her was appointed as full time business manager.

She has been a nurse for 25 years, practice nurse & practice manager for 16 of those. Andrea still practices as a nurse and is also business manager of her family run general practice. She helped establish and is a director of StHealthCare, a Social Enterprise Community Interest Company

Aodan is a senior director in the European Access to Medicines Centre of Excellence at GSK. He is an economist by training with over 15 years’ experience in working in both the public and private healthcare sectors. For the past 10 years he has worked in large pharma in a range of country, regional and global roles of increasing scope and responsibility. Prior to joining GSK in mid-2010 he was the senior director for Global Health Outcomes leading on Diabetes, Metabolism and Obesity at Eli Lilly where he worked closely with R&D and medical colleagues to embed payer needs and concepts of value into the early discovery process. Prior to this global role he was the EU GHO Endocrine lead at Eli Lilly and was engaged in pricing, reimbursement and access issues around the launch of Exenatide and Lilly’s re-engagement in the insulin market. In his roles he has worked with a broad range of payers at local and national levels, both in the US and EU. He has considerable experience in the design prospective observational research and has published across multiple therapeutic areas on, unmet need, quality of life, treatment pathways, resource utilisation and real world patient outcomes.

Hervé DREVOT is vice-president of CrossWorlds HealthCare Professionals. CWHCP is pan-European Think Tank made of clinical and non-clinical thought leaders who aspire to positively transform the health ecosystems.

In 2010-11, CWHCP sponsored an independent in-depth research at pan-European level to identify best practices and key opportunities for collaboration throughout the entire health value chain, with the ultimate objective to improve the benefits for the patient and increase healthcare system efficiency. Research has been conducted under the guidance of internationally renowned medical experts. Results are derived from over 100 face to face interviews with key constituents of the health ecosystems including patient groups, health care providers, policy makers and regulators.

Hervé started career at Deloitte in 1987. He held leading positions in several consultancies before he co-founded StarGen. StarGen is a strategy consultancy serving health and life sciences organizations to transform their value proposition and their collaborations to create lasting competitive advantages.

Hervé has gained an extended experience with Health Care and Life Sciences industries through a broad range of complex engagements (Strategic assessments, brand planning, competitive war gaming, advocacy strategy, Alliance, commercial excellence, organizational capability development) for major players across Europe, USA and Japan.

Most recently, he has been intensively involved with patient groups, academia, scientific societies, health care providers and industry in the development of collaborative projects throughout the cycle of innovation and adoption of medical practices.

Nicolas Touchot, Managing Director at Easton Associates, holds a Ph.D. in Molecular Biology from the Pierre et Marie Curie University in France and an MBA from the Kellogg Graduate School of Management. Before joining Easton Associates, Dr. Touchot was a principal in The Wilkerson Group in London. Prior to this he was part of the European management of Johnson & Johnson Interventional Systems where he specialized in market development and clinical testing. Earlier in his career, he worked as a research scientist for Princeton University.

At Easton Associates and The Wilkerson Group, Dr. Touchot has focused on the areas of oncology and cardiovascular diseases, building specific knowledge and expertise of these markets in Europe, and developing a team from London to help European and US clients with strategic questions pertaining to the European marketplace. More recently Dr. Touchot has developed a significant interest on the relationship between market access and clinical development. He believes that the Biopharma industry is facing a paradigm shift where pivotal trials must evolve to serve a dual purpose: answering regulator’s needs of course, while also supplying payers with reliable and clinically meaningful data that withstand critical market access evaluation.